A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Bristol-Myers Squibb
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Bristol-Myers Squibb
SymBio Pharmaceuticals
City of Hope Medical Center
Mayo Clinic
Cancer Research UK
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Boehringer Ingelheim
University of Nebraska
Columbia University
City of Hope Medical Center
Wake Forest University Health Sciences
Stanford University
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Massachusetts General Hospital
Fred Hutchinson Cancer Center
Columbia University
Goethe University
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Northwestern University
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Universität des Saarlandes
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
Mayo Clinic
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center